Although donor lymphocyte infusion (DLI) induces complete remissions in 70% of patients with relapsed chronic myeloid leukemia (CML) after allogeneic stem-cell transplantation (SCT), some patients are refractory to DLI by showing disease persistence. In a patient who received DLI for relapsed CML, we observed persisting molecular disease despite a hematological and cytogenetic remission in the absence of graft-versushost disease (GVHD). To determine the nature of this immune response, we isolated leukemia-reactive donor T-cell clones from the bone marrow (BM) of the patient at the time of clinical response. Four different types of CD8 þ HLA class I restricted T-cell clones were obtained that were cytotoxic against Ebstein-Barr virus-transformed B-cell lines (EBV-LCL) of the patient, but not the donor, indicating recognition of minor histocompatibility antigens (mHags). By using survival studies with CFSE labelled BM cells populations, a hematopoietic progenitor cell inhibition assay and direct morphological examination we showed that the T-cell clones recognized mature monocytic and myeloid cells, whereas immature BM progenitor cells were insufficiently lysed. This patient's refractoriness for DLI appears to be caused by inadequate lysis of progenitor cells by these cytotoxic T cells. These findings support the hypothesis that for eradication of CML a cytotoxic T-cell response against leukemic progenitor cells is essential.
Introduction
Allogeneic stem-cell transplantation (SCT) is the only curative treatment for chronic myeloid leukemia (CML). 1 After SCT, eradication of CML is mediated by a T-cell-dependent graftversus-leukemia (GVL) effect induced either by T cells present in the graft or by T cells administered by donor lymphocyte infusion (DLI) at a later time point. [2] [3] [4] After HLA-identical SCT, donor T cells that recognize minor histocompatibility antigens (mHags) on tumor cells are capable of mediating a GVL effect. 4, 5 Minor histocompatibility antigens (mHags) are immunogenic peptides derived from polymorphic proteins for which donor and recipient are disparate. Many mHags are broadly expressed on body tissues, explaining why the beneficial GVL effects of DLI are often accompanied by graftversus-host disease (GVHD). Several of these mHags have been characterized including HA-3, HA-8, various male-specific HY antigens and antigens encoded by the UGT2B17 and TMSB4Y gene. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Other mHags like HA-1, HA-2, BCL2A1 and the B-cell lineage restricted mHag HB-1 appear to have a relatively selective expression on hematopoietic cells. [17] [18] [19] [20] Disparity between donor and patient for these mHags can potentially result in a GVL response without severe GVHD.
In patients with a cytogenetic or hematological relapse of CML, DLI results in 70-80% complete molecular remissions. 3 However, some CML patients do not show any response, and others show partial or temporary responses with persistence of molecular disease. It is not known why these patients do not respond properly to DLI. To determine a possible mechanism for this DLI refractority we studied in detail a patient who received DLI for a hematological relapse of CML after HLA-identical sibling SCT. After obtaining a hematological and cytogenetic remission in the absence of any GVHD, persistence of molecular disease was observed despite multiple escalating doses of DLI. To determine the nature of this T-cell response, donor T cells were isolated from bone marrow (BM) of the patient at the time of clinical response, stimulated with original pre-transplantation CML mononuclear cells, cloned, expanded and characterized. Different types of CD8 þ cytotoxic T-cell clones were isolated that recognize mHags present on monocytic and mature myeloid CML cells, but not on CML progenitor cells. The isolation of this panel of CTL clones in the absence of any T cells against CML progenitor cells offers an explanation for the partial clinical response with disease persistence in this patient. Our results offer a new mechanism for DLI refractority, and strengthen the hypothesis that for adequate eradication of CML malignant progenitor cells need to be eradicated.
Case report
A 26-year-old male patient with chronic-phase CML pre-treated with hydroxyureum received an allogeneic peripheral blood stem cell transplantation from his HLA-identical brother after myeloablative conditioning with cyclophosphamide and totalbody irradiation. In vitro Campath-1H was used for T-cell depletion of the graft. Ten months after SCT donor chimerism decreased, and molecular disease was detected (Figure 1 ), prompting DLI administration (1 Â 10 7 mononuclear cells/kg). A second DLI (3 Â 10 7 mononuclear cells/kg) was given 3 months later owing to the rapid development of a hematological relapse. After the first and second DLI, a complete restoration of donor chimerism was observed associated with a decrease in BCR-ABL levels. Despite two additional escalating doses of DLI up to 5 Â 10 7 T cells/kg, BCR-ABL transcripts remained detectable. Forty months after SCT, the patient developed a localized myeloid blast crisis in the intraspinal space and adjacent extraspinal tissue of a thoracic vertebra. He was treated with local radiotherapy and systemic chemotherapy, resulting in a complete molecular remission. He again received DLI (1.5 Â 10 8 T cells/kg) and was further treated with imatinib.
Materials and methods

Patient and donor materials
After informed consent, bone marrow (BM) and peripheral blood (PB) samples were obtained from the patient, the HLAidentical sibling donor, a second untreated patient with CML, and an unrelated healthy BM donor. Bone marrow from the patient was obtained during chronic-phase and contained 20% BCR-ABL-positive cells as determined by fluorescein in situ hybridization (FISH). After Ficoll-Isopaque separation, mononuclear cells were cryopreserved. Epstein-Barr virus-transformed B-cell lines (EBV-LCL) and phytohemagglutininactivated T cells (PHA blasts) were generated using standard procedures.
Isolation and characterization of in vivo primed CML-reactive T-cell clones
Chronic myeloid leukemia reactive T-cell clones were isolated and expanded as described earlier. 21 Briefly, T cells were purified by negative selection using a pan T isolation kit (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) from BM mononuclear cells harvested during the clinical response after the second DLI. Purified T cells were incubated overnight with equal numbers of irradiated (15 Gy) recipient BM-derived CML cells isolated before SCT. After incubation, activated IFNgsecreting T cells were isolated using the IFNg secretion assay (Miltenyi Biotec), single cell sorted and expanded. Proliferating T-cell clones were selected and further expanded. For characterization of the T cell clones, the HLA class I and II restriction of the recognition of patient EBV-LCL was determined using anti-class I (W6/32) and anti-class II (PdV5.2) blocking antibodies in a 51 Cr-release assay, as described previously. 22 The patient was molecularly typed as HLA-A*01, A*11, B*08, B*57, Cw*06, Cw*07. Further restriction analysis was performed with the HLA B and C-reactive mAb (B 1.23.2) and the allele-specific human mAbs specific for HLA-A1/A11 (MUL7C7) and HLA-B8 (BVK1F9) as blocking mAbs. Determination of cytotoxicity of the T-cell clones against different EBV-LCLs sharing one or more HLA loci with the patient was used for further characterization of the HLA restriction of the recognition by the T-cell clones. The TCR BV chain usage of the T-cell clones was determined by polymerase chain reaction (PCR) and sequencing, as described previously. 21 
Cytotoxicity studies
To determine the cytotoxic capacity of the isolated T-cell clones against different cell populations, we performed 51 Cr-release cytotoxicity assays as described previously. 22 Patient as well as donor PHA blasts, EBV-LCL and pre-transplantation BM mononuclear cells were used as target cells. Two previously characterized cytotoxic T-cell clones were used as positive controls. Clone HA-1 is a CD8 þ T-cell clone recognizing HA-1H peptide in the context of HLA-A2. 21 Clone HY-A1 is a CD8 þ HLA-A1-restricted anti-HY T-cell clone recognizing a peptide derived from the DFFRY protein. 9 To be able to study cytotoxicity of different cell subsets for a longer period of time, we used a CFSE (carboxyfluorescein diacetate succinimidyl ester; Molecular Probes Europe, Leiden, The Netherlands) cytotoxicity assay. 23 
CFSE-labelled target cells were cocultured with unlabelled effector T cells for various time periods (4-72 h).
After culturing, lysis of specific target cell subsets was determined with flow cytometry, using counterstaining with CD3, CD19, CD14, CD34 and combined CD13/CD33 PEconjugated mAbs to detect T, B, monocytic, progenitor and myeloid cells, respectively. Both freshly thawed PB and BM mononuclear cells and cytokine-maturated BM cells were used as target cells. For this purpose, BM was cultured for 7-10 days in the presence of a cytokine mixture consisting of GM-CSF, G-CSF, IL-3, SCF, EPO, transferrin and b-mercaptoethanol.
The capability of the cytotoxic T-cell clones to lyse BM progenitor cells was also determined with the hematopoietic progenitor cell inhibition assay (PIA), by measuring T-celldependent inhibition of myeloid, monocytic and erythroid progeny formation, as described previously. 24, 25 Cytospin experiments for morphological analysis
To directly visualize the cell populations that are specifically killed by the T-cell clones, we used cytospin analysis. Effector T cells were cocultured with target cells for 48 h after which the cell mixture was gently spun down on glass slides. After drying, the cells were fixed, stained with hematoxylin-eosin and microscopically examined. As target cells, both freshly thawed BM cells and cytokine-induced maturated progeny from BM cells were used.
Results
Isolation and characterization of CML-reactive mHag-specific cytotoxic T cells
To isolate CML-reactive T cells, irradiated BM cells from the CML patient harvested before SCT were used to stimulate purified T cells from a BM sample taken at the time of response to DLI. With an IFNg capture assay, 78 proliferating clones were obtained, of which 65% were CD3 þ CD8 þ , 16% were CD3 þ CD4 þ and 19% were CD3 þ CD4ÀCD8À. The T cell clones were tested in a 51
Cr-release cytotoxicity assay against EBV-LCL, PHA blasts of patient and donor, and pre-transplantation patient BM material containing 20% BCR-ABL-positive cells. Ten of the 78 T-cell clones were found to be cytolytic against EBV-LCL of the patient (Table 1) , but not against EBV-LCL of the donor or PHA blasts of patient or donor (data not shown). Since the patient and donor are HLA identical, the observed differences in cytotoxicity against EBV-LCL of patient and donor indicated recognition of mHags. Two types of T-cell clones were found: rapidly lysing T-cell clones that showed strong lysis of EBV-LCL after 4 h incubation, and slowly lysing T-cell clones that showed limited lysis after 4 h but strong lysis after overnight incubation (Table 1 ). All 10 T-cell clones showed lysis of the pre-transplantation patient CML mononuclear cells up to 26% after 4 h or overnight incubation. All cytotoxic T-cell clones were CD3 þ CD8 þ and HLA class I-restricted (Table 1) . By performing 51 Cr-release cytotoxicity assays in the presence of different antibodies, the HLA restriction of the T-cell clones was found to be Cw6, Cw7 or B57. By using panels of different EBVLCLs sharing one or more HLA loci with the patient it was shown that the slowly lysing T-cell clones were HLA-Cw6-restricted and the rapidly lysing T-cell clones HLA-B57-restricted. Ten out of 24 HLA-Cw6-positive EBV-LCLs were recognized by the HLA-Cw6-restricted T-cell clones and five out of 14 HLA-B57-positive EBV-LCLs by the HLA-B57-restricted T-cell clones. The population frequencies of the mHags recognized by the T-cell clones are therefore approximately 40%.
Sequence analysis of the T cell receptor (TCR) showed that several of the 10 T-cell clones were identical; four different T-cell clones with unique clonal origin were found ( Table 1) . The HLA-Cw6-restricted T-cell clones were named C6-1 and C6-2, and the HLA-B57-restricted clones B57-1 and B57-2.
Lineage restricted cytotoxicity of the T-cell clones against specific subsets of target cells
The T-cell clones lysed EBV-LCLs but not PHA blasts of the patient, indicating recognition of mHags restricted to one or more specific cell lineages. The CFSE assay was used to further study the recognition of different subsets of cells from the patient. Freshly thawed pre-transplantation BM and PB mononuclear cells were CFSE labelled and cultured with T cells for 24 h. In contrast to the positive control T-cell clone HY-A1, which recognized all target cell populations, the isolated T-cell clones lysed only specific target cell subsets ( Table 2 ). The T-cell clones did not recognize CD19-positive B cells and CD3-positive T cells. CD13/33-positive mature myeloid cells were lysed, whereas CD34-positive progenitor cells were only marginally killed. However, it was difficult to draw definite conclusions on the basis of these results because the numbers of cells analyzed were small (Table 2) . We noticed that myeloid and monocytic cells were not stably present during culture but spontaneously underwent apoptosis. To obtain sufficient numbers of viable monocytic and myeloid cells for analysis, we cytokine-maturated pre-transplantation BM samples from the patient. Using these cytokine-maturated cells in the CFSE assay, we observed that all T-cell clones lysed monocytic cells within 4 h of incubation, whereas only the HLA-Cw6-restricted T-cell clones induced lysis of myeloid cells after 20 h of incubation ( Figure 2) . Lysis of these target cells took place at a rate comparable to the control HY-A1 clone.
Since the pre-transplantation BM mononuclear cells of the patient contained both normal and BCR-ABL-positive cells, it was not clear whether the CML and normal target cells expressed the mHags recognized by the T-cell clones. Therefore we obtained BM mononuclear samples containing 100% BCR-ABL-positive cells from another untreated HLA-Cw6-positive chronic-phase CML patient expressing the mHag recognized by the C6 T-cell clones. The mononuclear cell population from this patient contained 85% CD33 and CD34 double positive cells, phenotypically compatible with myeloid lineage-committed progenitor cells. The CFSE-based cytotoxicity assay was performed with freshly thawed progenitor cells and also with Cr-release assay with an effector:target ratio of 10:1. The number of target cells surviving in the absence of T cells was defined as 100%. For CD34, CD13/33, CD3 and CD19 positive cells these numbers were 100, 40, 3000 and 600 cells per well, respectively. Data represent the mean of three wells7standard deviation. Analysis of the CD14-positive cell population was not possible due to insufficient numbers.
cells that were cytokine maturated for 1 week. Since this patient was HLA-A2-positive and HLA-A1-negative we used the HLA-A2-restricted HA-1 T cell clone as a positive control in these experiments. As illustrated in Figure 3 , we observed that the T-cell clones did not adequately lyse immature CD34-positive progenitor cells, whereas cytokine-maturated myeloid and monocytic cells were lysed. We also obtained BM mononuclear cells from a normal HLA-Cw6-positive donor reacting with the C6 clones. Similar to the CML patient, we observed adequate lysis of cytokine-maturated myeloid and monocytic cells and insufficient lysis of progenitor cells in the CFSE cytotoxicity assay (Figure 3) . From these experiments, we concluded that the T-cell clones recognized a lineage restricted maturation antigen present on both normal and CML cells. Unfortunately, no BM mononuclear cells from other HLA-B57-positive individuals expressing the relevant mHag were available for further analysis of the B57 clones.
In BM, only a small number of hematopoietic progenitor/stem cells capable of generating myeloid, monocytic and erytroid progeny are present. As it is difficult to directly perform cytotoxicity assays on this cell population, we used a hematopoietic progenitor cell inhibition assay (PIA) to determine whether the cytotoxic T-cell clones were capable of lysing these progenitor cells. The T-cell clones were capable of partial inhibition of proliferation of the progenitor cells, whereas an almost complete abrogation of proliferation was found after incubation with the control T-cell clones HY-A1 or HA-1 (Figure 4) . These experiments further show the incomplete killing of the progenitor cells by the T-cell clones isolated from the patient.
Morphological characterization of the cell populations recognized by the T-cell clones
To visualize the specific lysis of maturated cells by the C6 clones, we performed cytospin analysis of T-cell clones cocultured with both immature progenitor BM cells and cytokine-maturated progeny from these cells. The immature progenitor cells consisted mainly of myeloblasts, whereas the cytokine-maturated progeny from these cells was a mixture of myelocytes, metamyelocytes, monocytes and granulocytes ( Figure 5 ). Again a clear difference in cytotoxic susceptibility for the C6 clones was observed between the immature and maturated target cell populations ( Figure 5 ). The control HA-1 clone showed equally effective lysis of both immature and maturated cells.
Discussion
Donor lymphocyte infusion can induce complete responses in the majority of CML patients with a hematological, cytogenetic or molecular relapse after allogeneic SCT. However, some patients show no response, whereas others have only temporary or partial responses. To gain more insight into the mechanism of insufficient responses to DLI we studied a CML patient with a hematological relapse who only partially responded to DLI after allogeneic SCT. Despite escalating doses of DLI, molecular disease persisted, which ultimately resulted in the development of a localized blast crisis.
T cells harvested at the time of an immune response after DLI administration were incubated with original CML material to activate a secondary immune response. CML reactive interferon-producing T cells were isolated with the use of the interferon secretion assay, single cell sorted, expanded and characterized. Previously, we have shown that this method allows the characterization of the complexity of tumor-reactive T cell responses in HLA-identical patient-donor combinations. 21, 26 From this DLI refractory patient, we isolated two different HLA-B57-restricted T-cell clones and two different HLA-Cw6-restricted T-cell clones. Using the 51 Cr-release assay, we showed that these clones were cytolytic against EBV-LCL of the patient, but not the donor, indicating recognition of mHags. Analysis of reactivity against different subsets of bone marrow cells revealed that the B57 clones lysed only monocytic cells, whereas the C6 clones were capable of lysing both monocytic and mature myeloid cells. Resting B cells and T cells were not recognized by any of the T-cell clones. Using three different assays including the hematopoietic progenitor inhibition assay, lysis of CFSE-labelled progenitor cells and direct visualization of cytospin preparations, we showed that immature CD34-positive cells representing BM progenitor cells were not or only marginally recognized by the T-cell clones. Furthermore, we observed a similar lysis pattern using BM cells from a normal HLA-Cw6-positive donor, indicating that these mHags are specifically expressed not only on CML, but also on normal myeloid cells. These results indicate that the T-cell clones recognized lineage-restricted antigens that were figure) from the unrelated HLA-Cw6-positive chronic myeloid leukemia (CML) patient. Target cells were cocultured with the Tcell clones HA-1 or C6-1 for 48 h, after which the cell mixture was spun down on glass slides and morphologically examined. Effector-target ratio was 1:1. Morphologically, the progenitor cells consisted mainly of myeloblasts, whereas the cytokine-maturated progeny from these cells contained myeloctes, granulocytes and monocytes. In contrast to the control clone HA-1 that killed all target cells, a clear difference between lysis of immature and maturated target cells by the C6 clones was observed.
expressed during maturation of progenitor cells into myeloid and monocytic cells and during EBV-induced transformation of B-cells.
On the basis of differences in lysis of EBV-LCLs, the isolated T-cell clones were subdivided into slowly and rapidly lysing clones. In contrast, no differences were observed in the lysis of monocytic cells that were rapidly killed by all T-cell clones. The observed differences should therefore not be attributed to the T-cell clones, but are more likely to be inherent to the recognition of EBV-LCLs, and may be caused by different levels of peptide presentation by the HLA molecules on the target cells.
The T-cell clones were harvested from the patient at the moment of an immune response that resulted in a large reduction of CML tumor load as exemplified by a 3 log decrease in BCR-ABL levels. In CML, the bulk of the tumor consists of maturated myeloid and monocytic cells. Therefore, the T-cell clones isolated at the time of this immune response may well have been instrumental in the elimination of the majority of the tumor bulk, resulting in an excellent clinical response. However, an immune response with these T cells would have left the CML progenitor cells unharmed, resulting in continuing molecular disease, as was observed in the patient. Despite a seemingly good response to DLI, proliferating immature cells continued to be present in the BM, posing a continuous threat for the development of a blast crisis, which eventually developed in the patient.
The importance of eliciting an immune response against progenitor cells has already been described in earlier studies. In post transplantation patients with adequate responses to DLI for relapsed CML, we illustrated the correlation between the presence in vivo of T cells recognizing CML progenitor cells and complete remissions. 21, 24, 26, 27 As malignant disease can only be maintained by leukemic stem cells with self-renewal capabilities, 28, 29 it can be hypothesized that for definite control of malignant disease, an immune response against leukemic progenitor cells is needed. Cancer stem cells have been demonstrated not only in CML, but also in acute leukemia, myelodysplasia and breast cancer. 29 Failure of tumor eradication owing to an immune response against mature cells instead of progenitor cells may play a role not only in CML, but also in other malignant diseases.
In conclusion, different types of cytotoxic T cells have been isolated from a relapsed CML patient with molecular persistence of disease after repeated DLI infusions. These T-cell clones recognized lineage-restricted antigens present on EBV-LCLs, monocytes and mature myeloid cells, but not on progenitor cells. These T-cell clones differ from T cells isolated from CML patients with complete responses to DLI that recognized both mature and progenitor cells. 21, 26, 27 Although the frequency of this phenomenon cannot be determined from this single patient case, it is tempting to relate the refractoriness of this patient for DLI with persistence of molecular disease to the inadequate lysis of progenitor cells by cytotoxic T cells. These findings further support the hypothesis that for adequate eradication of CML, a cytotoxic T cell response against leukemic progenitor cells is needed.
